Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05229952 · ClinicalTrials.gov registry record · NA

Assessment of Endogenous Oxalate Synthesis

A NA study of Healthy and Obesity, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT05229952: Completed NA study of Healthy and Obesity, sponsored by University of Alabama at Birmingham.

NCT05229952 is a NA study of Healthy and Obesity that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 23 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05229952, a NA study of Healthy and Obesity, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This study aims to determine the daily rate of endogenous synthesis of oxalate using carbon 13 oxalate isotope tracer technique and a low-oxalate controlled diet.

Primary Outcome

Daily oxalate synthesis rate (mg/day) determined by the 13c2-oxalate infusion method

Interventions

  • DIETARY_SUPPLEMENT Low-oxalate controlled diet
  • OTHER Primed, continuous intravenous infusion of 13C2-oxalate

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2022-02-10
Est. Completion 2024-09-09
Phase NA
University of Alabama at Birmingham

1,160 total trials

What the finished NCT05229952 record still lists

NCT05229952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).

The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Low-oxalate controlled diet is the first listed.

NCT05229952 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT05229952 about?

NCT05229952 is a clinical study titled "Assessment of Endogenous Oxalate Synthesis". This study aims to determine the daily rate of endogenous synthesis of oxalate using carbon 13 oxalate isotope tracer technique and a low-oxalate controlled diet.

What is the current status of trial NCT05229952?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2022-02-10. Estimated completion is 2024-09-09.

What conditions does trial NCT05229952 study?

This clinical trial studies the following conditions: Healthy, Obesity, Kidney Stone.

What interventions are being tested in trial NCT05229952?

The interventions under investigation include: Low-oxalate controlled diet (DIETARY_SUPPLEMENT), Primed, continuous intravenous infusion of 13C2-oxalate (OTHER).

Who is sponsoring clinical trial NCT05229952?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05229952 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05229952's enrollment target sits among peer trials

23 838th of 1090 higher than 248 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05229952, the US trial registry maintained by the National Library of Medicine. NCT05229952 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.